Standard

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma? / Favreau, Mérédis; Vanderkerken, Karin; Elewaut, Dirk; Venken, K.; Menu, Eline.

In: Oncotarget, Vol. 7, No. 17, 26.04.2016, p. 23128-40.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

BibTeX

@article{b452c8e96f3f466fa850b720d3959024,
title = "Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?",
abstract = "Natural killer T (NKT) cells constitute a unique subset of innate-like T lymphocytes which differ from conventional T cells by recognizing lipid antigens presented by the non-polymorphic major histocompatibility complex (MHC) I-like molecule CD1d. Despite being a relatively infrequent population of lymphocytes, NKT cells can respond rapidly upon activation with glycosphingolipids by production of cytokines which aim to polarize different axes of the immune system. Due to their dual effector capacities, NKT cells can play a vital role in cancer immunity, infection, inflammation and autoimmune diseases. It is believed that modulation of their activity towards immune activation can be a useful tool in anti-tumor immunotherapeutic strategies. Here we summarize the characteristics of NKT cells and discuss their involvement in immunosurveillance. Furthermore, an update is given about their role and the progress that has been made in the field of multiple myeloma (MM). Finally, some challenges are discussed that are currently hampering further progress.",
author = "M{\'e}r{\'e}dis Favreau and Karin Vanderkerken and Dirk Elewaut and K. Venken and Eline Menu",
year = "2016",
month = "4",
day = "26",
doi = "10.18632/oncotarget.7440",
language = "English",
volume = "7",
pages = "23128--40",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

RIS

TY - JOUR

T1 - Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

AU - Favreau, Mérédis

AU - Vanderkerken, Karin

AU - Elewaut, Dirk

AU - Venken, K.

AU - Menu, Eline

PY - 2016/4/26

Y1 - 2016/4/26

N2 - Natural killer T (NKT) cells constitute a unique subset of innate-like T lymphocytes which differ from conventional T cells by recognizing lipid antigens presented by the non-polymorphic major histocompatibility complex (MHC) I-like molecule CD1d. Despite being a relatively infrequent population of lymphocytes, NKT cells can respond rapidly upon activation with glycosphingolipids by production of cytokines which aim to polarize different axes of the immune system. Due to their dual effector capacities, NKT cells can play a vital role in cancer immunity, infection, inflammation and autoimmune diseases. It is believed that modulation of their activity towards immune activation can be a useful tool in anti-tumor immunotherapeutic strategies. Here we summarize the characteristics of NKT cells and discuss their involvement in immunosurveillance. Furthermore, an update is given about their role and the progress that has been made in the field of multiple myeloma (MM). Finally, some challenges are discussed that are currently hampering further progress.

AB - Natural killer T (NKT) cells constitute a unique subset of innate-like T lymphocytes which differ from conventional T cells by recognizing lipid antigens presented by the non-polymorphic major histocompatibility complex (MHC) I-like molecule CD1d. Despite being a relatively infrequent population of lymphocytes, NKT cells can respond rapidly upon activation with glycosphingolipids by production of cytokines which aim to polarize different axes of the immune system. Due to their dual effector capacities, NKT cells can play a vital role in cancer immunity, infection, inflammation and autoimmune diseases. It is believed that modulation of their activity towards immune activation can be a useful tool in anti-tumor immunotherapeutic strategies. Here we summarize the characteristics of NKT cells and discuss their involvement in immunosurveillance. Furthermore, an update is given about their role and the progress that has been made in the field of multiple myeloma (MM). Finally, some challenges are discussed that are currently hampering further progress.

U2 - 10.18632/oncotarget.7440

DO - 10.18632/oncotarget.7440

M3 - Article

C2 - 26895468

VL - 7

SP - 23128

EP - 23140

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -

ID: 23491896